Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.
Hosted on MSN23h
Drugs approved for other diseases may unlock a faster path to Alzheimer’s treatment, UNLV researcher saysDoctor Jeffrey Cummings is world-renowned in the field of Alzheimer's research and he leads UNLV's Center for Transformative Neuroscience.
News Medical on MSN5d
Lecanemab and donanemab slow Alzheimer’s decline, but is the benefit worth the cost?Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...
Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in ...
Medpage Today on MSN3d
Alzheimer's Patients May Gain Months of Independent Living With TreatmentAlzheimer's patients with a baseline CDR-SB score of 3.5 could expect approximately 4 additional months (95% CI 2-7 months) ...
More than a decade after hosting clinical trials for two medications now commonly used to slow the progression of Alzheimer’s ...
Clinical Dementia Rating (CDR) scores can help doctors tell when people with Alzheimer’s disease experience lower ...
In the past two years, the Food and Drug Administration has approved two novel Alzheimer's therapies, based on data from ...
Your doctor might suggest taking one of the newer medications such as lecanemab or donanemab, which have been shown in clinical trials to clear plaque-causing amyloid proteins from the brain that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback